Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy

Lancet

Volumn 351, Issue 9111, 1998, Pages 1233-1237

  Osterziel, Karl Josef ^a   Strohm, Oliver ^a   Schuler, Jochen ^b   Friedrich, Matthias ^a   Hänlein, Dankward ^a   Willenbrock, Roland ^a   Anker, Stefan D ^c   Poole Wilson, Philip A ^c   Ranke, Michael B ^d   Dietz, Rainer ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MARTIN LUTHER KRANKENHAUS   (Germany)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HEART DILATATION; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE SIZE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032565361     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)11329-0     Document Type: Article

References (30)

1. 1 Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994; 331: 1564-75.
2. 2 Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-42.
3. 3 Levin HR, Oz MC, Chen JM, Packer M, Rose EA, Burkhoff D. Reversal of chronic ventricular dilation in patients with end-stage cardiomyopathy by prolonged mechanical unloading. Circulation 1995; 91: 2717-20.
4. 4 Batista RJ, Santos JL, Takeshita N, Bocchino L, Lima PN, Cunha MA. Partial left ventriculectomy to improve left ventricular function in end-stage heart disease. J Card Surg 1996; 11: 96-97.
5. 5 Thuesen L, Christiansen JS, Sorensen KE, Jorgensen JO, Orskov H, Henningsen P. Increased myocardial contractility following growth hormone administration in normal man. Dan Med Bull 1988; 35: 193-96.
6. 6 Fazio S, Sabatini D, Capaldo B, et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 809-14.
7. 7 Germain P, Roul G, Kastler B, Mossard J-M, Bareiss P, Sacrez A. Inter-study variability in left ventricular mass measurement. Eur Heart J 1992; 13: 1011-19.
8. 8 Buser PT, Auffermann W, Holt WW, et al. Noninvasive evaluation of global left ventricular function with use of cine nuclear magnetic resonance. J Am Coll Cardiol 1989; 13: 1294-1300.
9. 9 Katz J, Milliken MC, Stray-Gundersen JS, et al. Estimation of human myocardial mass with MR imaging. Radiology 1988; 169: 495-98.
10. 10 Arts T, Veenstra PC, Reneman RS. Epicardial deformation and left ventricular wall mechanisms during ejection in the dog. Am J Physiol 1982; 243: H379-90.
11. 11 Celniker AC, Chen AB, Wert RM, Sherman BM. Variability in the quantitation of circulating growth hormone using commercial immunoassays. J Clin Endocrinol Metab 1989; 68: 469-76.
12. 12 Juul A, Dalgaard P, Blum WF, et al. Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-I, IGF-II, IGFBP-1, IGFBP-2, age, sex, bodymass index, and pubertal maturation. J Clin Endocrinol Metab 1995; 80: 2534-42.
13. 13 Blum WF. Insulin-like growth factors and their binding proteins. In: Ranke MB, ed. Diagnostics of endocrine function in children and adolescents. Heidelberg: JA Earth, 1996: 190-218.
14. 14 Frustaci A, Perrone GA, Gentiloni NR, Ruso Ma. Reversible dilated cardiomyopathy due to growth hormone deficiency. Am J Clin Pathol 1992; 97: 503-11.
15. 15 Cittadini A, Strömer H, Katz SE, et al. Differential cardiac effects of growth hormone and insulin-like growth factor-I in the rat. Circulation 1996; 93: 800-09.
16. 16 Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J. Insulin-like growth factor-I enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95: 619-27.
17. 17 Cittadini A, Grossman JD, Napoli R, et al. Growth hormone attenuates early left ventricular remodeling and improves cardiac function in rats with large myocardial infarction. J Am Coll Cardiol 1997; 29: 1109-16.
18. 18 Pouleur HG, Konstam MA, Udelson JE, Rousseau MF. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. J Am Coll Cardiol 1993; 22: 43A-48A.
19. 19 Cheng W, Li B, Kajstura J, et al. Stretch-induced programmed myocyte cell death. J Clin Invest 1995; 96: 2247-59.
20. 20 Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995; 92: 8031-35.
21. 21 Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994; 94: 1621-28.
22. 22 Donaldson DL, Hollowell JG, Pan FP, Gifford RA, Moore WV. Growth hormone secretory profiles: variation on consecutive nights. J Pediatr 1989; 115: 51-56.
23. 23 Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993; 76: 1610-16.
24. 24 Anker SD, Chua TP, Ponikowski P, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997; 96: 526-34.
25. 25 Giustina A, Lorusso R, Borghetti V, Bugari G, Misitano V, Alfieri O. Impaired spontaneous growth hormone secretion in severe dilated cardiomyopathy. Am Heart J 1996; 131: 620-22.
26. 26 Valcavi R, Gaddi O, Zini M, Iavicoli M, Mellino U, Portioli I. Cardiac performance and mass in adults with hypopituitarism: effects of one year of growth hormone treatment. J Clin Endocrinol Metab 1995; 80: 659-66.
27. 27 Cuneo RC, Salomon F, Wiles CM, Hesp R, Sönksen PH. Growth hormone treatment in growth hormone-deficient adults. J Appl Physiol 1991; 70: 695-700.
28. 28 Beshyah SA, Shahi M, Skinner E, Sharp P, Foale R, Johnston SG. Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. Eur J Endocrinol 1994; 130: 451-58.
29. 29 Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol (Oxf) 1994; 41: 85-93.
30. 30 Johannsson G, Bjarnason R, Bramnert M, et al. The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH-binding protein, body mass index, age, and gender. J Clin Endocrinol Metab 1996; 81: 1575-81.